AVTX (Avalo Therapeutics) Goodwill: $10.50 Mil (As of Mar. 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $17.87
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Goodwill?

Avalo Therapeutics AVTX -0.72% 23 Goodwill is $10.50 Mil as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Avalo Therapeutics's goodwill for the quarter that ended in Mar. 2026 was $10.50 Mil.


Avalo Therapeutics  (NAS:AVTX) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Avalo Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Goodwill-to-Asset (A: Dec. 2025 )=Goodwill/Total Assets
=10.502/116.458
=0.09

Avalo Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

Goodwill-to-Asset (Q: Mar. 2026 )=Goodwill/Total Assets
=10.502/99.885
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Avalo Therapeutics Goodwill Related Terms


Avalo Therapeutics Goodwill Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Goodwill Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Goodwill
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.41 14.41 10.50 10.50 10.50

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.50 10.50 10.50 10.50 10.50
AVTX
23GF Score
Avalo Therapeutics Inc AVTX
Goodwill is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

Frequently Asked Questions Learn more about Goodwill →
What does a Goodwill of $10.50 Mil mean?
Avalo Therapeutics (AVTX) has a Goodwill of $10.50 Mil as of Mar. 2026. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' Goodwill too high?
Avalo Therapeutics' current Goodwill is $10.50 Mil. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Goodwill compare to EVMN and TBPH?
Avalo Therapeutics' Goodwill of $10.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill for a Biotechnology company?
A good Goodwill depends on the Biotechnology industry context. However, Goodwill should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill mean?
A high Goodwill can signal that a stock is expensive relative to its fundamentals. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current Goodwill is $10.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $17.87 — trading 59466.7% above its estimated fair value. The current Goodwill is $10.50 Mil. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill calculated?
Goodwill is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Goodwill is $10.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $17.87 is trading 59466.7% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Goodwill: $10.50 Mil
  • GF Value™: $0.03 vs. price of $17.87 (59466.7% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

Goodwill is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.87
Price
$0.03
GF Value